BioPharmSignal logoBioPharmSignal

Biotech News

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance

Si-Bone (SIBN)Si-BoneEarnings

Delivered ~ 21% worldwide revenue growth, ~ 5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.7 million , representing growth of 20.6% U.S.

Related news

SIBNSi-Bone2026-08-03 20:09 EST

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

SIBNSi-Bone2026-05-11 20:09 EST

SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance

View all latest news

Si-Bone

Spinopelvic Procedural Solutions SI-BONE is a global medical-device company developing procedural solutions for patients with compromised bone, with a particular focus on the sacropelvic and spinopelvic anatomy. iFuse Technology Platform Its portfolio is built around the iFuse family of implants and instruments. Products include...

Recent company news

SIBNSi-Bone2026-08-03 20:09 EST

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

SIBNSi-Bone2026-07-20 20:09 EST

SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026

SIBNSi-Bone2026-06-04 20:09 EST

SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026

SIBNSi-Bone2026-05-11 20:09 EST

SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance

SIBNSi-Bone2026-04-30 20:09 EST

SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026

Stock data

Close
18.14 USD
Market cap
621.33M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States